EAN 2020: THE EFFECTIVENESS AND SAFETY OF BTK INHIBITOR EVOBRUTINIB IN THE TREATMENT OF RECURRENT MULTIPLE SCLEROSIS ARE GOOD
-
Last Update: 2020-05-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
At the 2020 European Society of Neurology (EAN) Virtual Conference, EMD Serono Pharmaceuticals published long-term efficacy and safety data for evobrutinib for the treatment of recurrent multiple sclerosis (RMS), a research, oral, highly selective Bruton tyrosine kinase (BTK) inhibitorLuciano Rossetti, head of global research and development at EMD Serono, said: "These data show that evobrutinib has a sustained and significant impact on annual recurrence rate (ARR) within 108 weeksWe are also encouraged by the security data for evobrutinib"During the double-blind study period, patients receiving evobrutinib 75mg BID (twice a day) had an annual recurrence rate (ARR) of 0.11 (95% CI 0.04-0.25) at 48 weeks and 0.12 (95% CI 0.06-0.22) at 108 cyclesmultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system and is the most common non-traumatic disabling neurological disease in young peopleIt is estimated that about 2.3 million people worldwide suffer from MSAlthough symptoms may vary, the most common symptoms of MS include blurred vision, numbness or tingling
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
